These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 22836362)

  • 1. Osteopetrosis rescue upon RANKL administration to Rankl(-/-) mice: a new therapy for human RANKL-dependent ARO.
    Lo Iacono N; Blair HC; Poliani PL; Marrella V; Ficara F; Cassani B; Facchetti F; Fontana E; Guerrini MM; Traggiai E; Schena F; Paulis M; Mantero S; Inforzato A; Valaperta S; Pangrazio A; Crisafulli L; Maina V; Kostenuik P; Vezzoni P; Villa A; Sobacchi C
    J Bone Miner Res; 2012 Dec; 27(12):2501-10. PubMed ID: 22836362
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Infantile malignant, autosomal recessive osteopetrosis: the rich and the poor.
    Villa A; Guerrini MM; Cassani B; Pangrazio A; Sobacchi C
    Calcif Tissue Int; 2009 Jan; 84(1):1-12. PubMed ID: 19082854
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RANKL cytokine: from pioneer of the osteoimmunology era to cure for a rare disease.
    Lo Iacono N; Pangrazio A; Abinun M; Bredius R; Zecca M; Blair HC; Vezzoni P; Villa A; Sobacchi C
    Clin Dev Immunol; 2013; 2013():412768. PubMed ID: 23762088
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A RANKL G278R mutation causing osteopetrosis identifies a functional amino acid essential for trimer assembly in RANKL and TNF.
    Douni E; Rinotas V; Makrinou E; Zwerina J; Penninger JM; Eliopoulos E; Schett G; Kollias G
    Hum Mol Genet; 2012 Feb; 21(4):784-98. PubMed ID: 22068587
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human osteoclast-poor osteopetrosis with hypogammaglobulinemia due to TNFRSF11A (RANK) mutations.
    Guerrini MM; Sobacchi C; Cassani B; Abinun M; Kilic SS; Pangrazio A; Moratto D; Mazzolari E; Clayton-Smith J; Orchard P; Coxon FP; Helfrich MH; Crockett JC; Mellis D; Vellodi A; Tezcan I; Notarangelo LD; Rogers MJ; Vezzoni P; Villa A; Frattini A
    Am J Hum Genet; 2008 Jul; 83(1):64-76. PubMed ID: 18606301
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structure-based development of a receptor activator of nuclear factor-kappaB ligand (RANKL) inhibitor peptide and molecular basis for osteopetrosis.
    Ta HM; Nguyen GT; Jin HM; Choi J; Park H; Kim N; Hwang HY; Kim KK
    Proc Natl Acad Sci U S A; 2010 Nov; 107(47):20281-6. PubMed ID: 21059944
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Osteoclast-poor osteopetrosis.
    Sobacchi C; Abinun M
    Bone; 2022 Nov; 164():116541. PubMed ID: 36031188
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Osteoclast-poor human osteopetrosis due to mutations in the gene encoding RANKL.
    Sobacchi C; Frattini A; Guerrini MM; Abinun M; Pangrazio A; Susani L; Bredius R; Mancini G; Cant A; Bishop N; Grabowski P; Del Fattore A; Messina C; Errigo G; Coxon FP; Scott DI; Teti A; Rogers MJ; Vezzoni P; Villa A; Helfrich MH
    Nat Genet; 2007 Aug; 39(8):960-2. PubMed ID: 17632511
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Insertion Mutation in Tnfrsf11a Causes a Paget's Disease-Like Phenotype in Heterozygous Mice and Osteopetrosis in Homozygous Mice.
    Alonso N; Wani S; Rose L; Van't Hof RJ; Ralston SH; Albagha OME
    J Bone Miner Res; 2021 Jul; 36(7):1376-1386. PubMed ID: 33724536
    [TBL] [Abstract][Full Text] [Related]  

  • 10. RANK-dependent autosomal recessive osteopetrosis: characterization of five new cases with novel mutations.
    Pangrazio A; Cassani B; Guerrini MM; Crockett JC; Marrella V; Zammataro L; Strina D; Schulz A; Schlack C; Kornak U; Mellis DJ; Duthie A; Helfrich MH; Durandy A; Moshous D; Vellodi A; Chiesa R; Veys P; Lo Iacono N; Vezzoni P; Fischer A; Villa A; Sobacchi C
    J Bone Miner Res; 2012 Feb; 27(2):342-51. PubMed ID: 22271396
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New knowledge on critical osteoclast formation and activation pathways from study of rare genetic diseases of osteoclasts: focus on the RANK/RANKL axis.
    Crockett JC; Mellis DJ; Scott DI; Helfrich MH
    Osteoporos Int; 2011 Jan; 22(1):1-20. PubMed ID: 20458572
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Malignant autosomal recessive osteopetrosis caused by spontaneous mutation of murine Rank.
    Kapur RP; Yao Z; Iida MH; Clarke CM; Doggett B; Xing L; Boyce BF
    J Bone Miner Res; 2004 Oct; 19(10):1689-97. PubMed ID: 15355564
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutations within the TNF-like core domain of RANKL impair osteoclast differentiation and activation.
    Cheng T; Pavlos NJ; Wang C; Tan JW; Lin JM; Cornish J; Zheng MH; Xu J
    Mol Endocrinol; 2009 Jan; 23(1):35-46. PubMed ID: 19008464
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fos plays an essential role in the upregulation of RANK expression in osteoclast precursors within the bone microenvironment.
    Arai A; Mizoguchi T; Harada S; Kobayashi Y; Nakamichi Y; Yasuda H; Penninger JM; Yamada K; Udagawa N; Takahashi N
    J Cell Sci; 2012 Jun; 125(Pt 12):2910-7. PubMed ID: 22454522
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel genetic models of osteoporosis by overexpression of human RANKL in transgenic mice.
    Rinotas V; Niti A; Dacquin R; Bonnet N; Stolina M; Han CY; Kostenuik P; Jurdic P; Ferrari S; Douni E
    J Bone Miner Res; 2014; 29(5):1158-69. PubMed ID: 24127173
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SNX10 mutations define a subgroup of human autosomal recessive osteopetrosis with variable clinical severity.
    Pangrazio A; Fasth A; Sbardellati A; Orchard PJ; Kasow KA; Raza J; Albayrak C; Albayrak D; Vanakker OM; De Moerloose B; Vellodi A; Notarangelo LD; Schlack C; Strauss G; Kühl JS; Caldana E; Lo Iacono N; Susani L; Kornak U; Schulz A; Vezzoni P; Villa A; Sobacchi C
    J Bone Miner Res; 2013 May; 28(5):1041-9. PubMed ID: 23280965
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fetal liver cells transplanted in utero rescue the osteopetrotic phenotype in the oc/oc mouse.
    Tondelli B; Blair HC; Guerrini M; Patrene KD; Cassani B; Vezzoni P; Lucchini F
    Am J Pathol; 2009 Mar; 174(3):727-35. PubMed ID: 19218349
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advances in osteoclast biology resulting from the study of osteopetrotic mutations.
    Segovia-Silvestre T; Neutzsky-Wulff AV; Sorensen MG; Christiansen C; Bollerslev J; Karsdal MA; Henriksen K
    Hum Genet; 2009 Jan; 124(6):561-77. PubMed ID: 18987890
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in bone cell biology.
    Hofbauer LC; Heufelder AE
    J Mol Med (Berl); 2001 Jun; 79(5-6):243-53. PubMed ID: 11485016
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Osteopetrosis: genetics, treatment and new insights into osteoclast function.
    Sobacchi C; Schulz A; Coxon FP; Villa A; Helfrich MH
    Nat Rev Endocrinol; 2013 Sep; 9(9):522-36. PubMed ID: 23877423
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.